Targazyme, Inc. products

The therapeutic value of any cell-based therapy is highly dependent on the ability of cells to reach the diseased organ to exert their therapeutic function. Our core technology – ex vivo fucosylation – enhances the physiological mechanism by which cells circulating in the blood stream reach the diseased tissue. This mechanism is triggered by the interaction between selectins (P and E-selectins) found on the lining of blood vessels and epithelium of a multitude of tissues such as the bone marrow and certain cell-surface biomolecules to which a sugar (fucose) is enzymatically added by fucosylation.